Long term safety and efficacy of rabies monoclonal antibody in post-exposure prophylaxis

1. The rate of adverse events and seroresponse was similar between groups. 2. There were no incidents of rabies development in either group after 1-year. Evidence Rating Level: 1 (Excellent) Study Rundown: Rabies is a universally fatal disease, and rabies monoclonal antibody (RmAb) was approved in 2016 for passive prophylaxis. This randomized controlled trial aimed […]